TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04501276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG116
Description: For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG116
Description: For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG116
Description: For monotherapy ADG116 (Part A), ADG116 will be administered IV over 60 90 minutes until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG106
Description: For the ADG116-ADG106 combination regimen, ADG116 and ADG106 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti PD1 drug
Description: For the ADG116-anti PD1 combination regimen, ADG116 and anti PD1 will be administered until disease progression, intolerable toxicities, or withdrawal of consent, or up to 2 years.
Study: NCT02470949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Social Status
Description: The participants will be randomized to the Low Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Social Status
Description: The participants will be randomized to the High Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
Study: NCT00325013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA)
Description: 800mg twice a day for 1 year
Study: NCT01611467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223
Description: 20 mg oral CC-223 capsule containing a microtracer of \[14C\]-CC-223 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223
Description: 20 mg oral CC-223 capsule containing a microtracer of \[14C\]-CC-223 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223
Description: 20-mg oral CC-223 tablet under fasting or fed conditions
Study: NCT04445064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO102
Description: 100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO103
Description: 100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
Study: NCT02191163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antistax®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03689504

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based nutrition education
Description: Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based family gardening
Description: Health promoters will facilitate the building and maintenance of a family home garden using a square foot or container gardening method.
Study: NCT03798912

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: RaniPill capsule containing octreotide
Description: Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RaniPill capsule containing octreotide
Description: Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RaniPill capsule containing octreotide
Description: Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RaniPill capsule containing octreotide
Description: Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule.
Study: NCT02641366

Intervention type: DEVICE
Intervention: Electromagnetic tracking
Description: The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.

Intervention type: DEVICE
Intervention: Electromagnetic tracking
Description: The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.

Intervention type: PROCEDURE
Intervention: Tremor kinetics after DBS
Description: We will fit the patient with the electromagnetic sensors and then perform routine outpatient neurologic examinations with their DBS system in both the DBS on and the DBS off settings.

Intervention type: PROCEDURE
Intervention: Tremor kinetics before and after DBS
Description: We will perform two testing sessions: the first session will be performed during a routine preoperative visit, the second session will be performed during a routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
Study: NCT04729920

Intervention type: DEVICE
Intervention: Mechanical insufflation/exsufflation device (MI-E)
Description: download of device (MI-E) data and self-reported satisfaction with the device
Study: NCT01116219

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab, erlotinib
Description: * Bevacizumab 7.5 mg/kg i.v. every 3 weeks and~* Erlotinib 150 mg p.o. daily until progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab, pemetrexed, cisplatin
Description: Induction chemotherapy with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. and~* Cisplatin\* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression. Followed by maintenance therapy in patients without disease progression with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression.
Study: NCT05209932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online New Beginnings Program (eNBP)
Description: The eNBP is a five-hour, asynchronous, fully web-based adaptation of the group-based NBP that can be used on a smart phone, tablet or computer. Separate versions for fathers and mothers consist of the same didactic content and interactive exercises, with gender appropriate references, testimonials and video skills demonstrations.
Study: NCT00259220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythomycin
Description: erythomycin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: gastric lavage alone
Description: gastric lavage alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erythromycine and gastric lavage
Description: erythromycine and gastric lavage
Study: NCT02408055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995
Study: NCT02260908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 30 mg subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline in equal volume to active comparator given subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
Study: NCT00469755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene Gel, 0.1%
Description: Apply once daily in the evening for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene Cream, 0.1%
Description: Apply once daily in the evening for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
Description: Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
Study: NCT00186056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Glucocorticoid antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Inactive placebo tab
Study: NCT03761043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Behavior Change Intervention
Description: IV to PO antimicrobial conversion guidelines for nurses, nurse in-services and internet education sessions, IV to PO antimicrobial conversion health record reminder, endorsement from antimicrobial stewardship program, prescribers, and nurse educators.
Study: NCT00810719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.
Study: NCT01015482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam Infusion
Study: NCT02119273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: See arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm description
Study: NCT01593540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: metal-free interdental brush
Description: one time per day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: metal-core interdental brush
Description: one time per day
Study: NCT00687076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Daily dose of 10 mg of Ezetimibe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niaspan
Description: Daily dose of 1500 mg of Niaspan
Study: NCT00978809

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epley maneuver

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semont maneuver
Study: NCT02137590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spanish Black Radish product
Study: NCT01809418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: keePAP
Study: NCT02033018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Aflibercept intravitreal injection
Study: NCT02158754

Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD (ASGES)
Study: NCT01842724

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motec total wrist arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remotion total wrist arthroplasty
Study: NCT01738308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Healing Touch
Description: When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Healing Touch Sham Treatment
Description: The untrained in energy work study staff will be at the bedside when the patient is first brought to the PACU. The practitioner will then place one hand on the center of the patient's chest in the high heart area. This will continue until parents are called to the bedside
Study: NCT01696578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BF-CBT and group physiotherapy
Description: Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BF-CBT and group physiotherapy
Description: Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis
Study: NCT02768194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stannous fluoride
Description: Dentifrice containing 0.454% stannous fluoride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate
Description: Dentifrice containing 0.76% sodium monofluorophosphate

Intervention type: OTHER
Group type: OTHER
Intervention: Mineral water
Description: Commercially available mineral water
Study: NCT02774421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab after SubQ GM-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with SubQ GM-CSF
Study: NCT02237976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine practice
Study: NCT03482323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Our exercise class intervention is based on current best evidence and will be tailored for each participant's ability for exercise. The exercise classes is also designed to fit into the guidelines for exercise in adults aged 18 years and above with a long term health condition. During the 12 weeks in the training, exercises will be varied (mixing up time spent on bikes and walking) along with the intensities of exercise varied to keep the classes more engaging for participants and maintaining compliance to the programme.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai-Chi
Description: Our tai-chi classes will be based on a 24-form Yang style of tai-chi exercise set.
Study: NCT00753935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enteric-coated aspirin
Description: enteric-coated aspirin 81mg daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chewable aspirin
Description: chewable aspirin 81mg daily for 2 weeks
Study: NCT02125006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups. To assess therapist adherence to the protocol, sessions will be recorded. A random selection of 50% of sessions will be rated by an MBSR trainer who completed the University of Massachusetts Centre for Mindfulness in Medicine, Health Care and Society Teacher Development Intensive using a checklist of specified treatment components. A percentage score for each session rated will be calculated to determine therapist adherence.
Study: NCT00116857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline/omega-3
Description: Sertraline (50 mgs) plus omega-3 (2 grams)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline/Corn Oil
Description: Sertraline (50 mgs) plus corn oil (2 grams) (placebo)
Study: NCT01603641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Participants received intramuscular injections of botulinum toxin Type A into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
Study: NCT02112994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebelipase Alfa
Description: IV infusion of sebelipase alfa
Study: NCT01047761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 3 month exercise intervention, three days a week Progressive in duration - up to 1 hour daily; Progressive in intensity~Multi-modal exercise program includes a) aerobic - walking, b) resistive training with therabands and core exercises, and c) breathing exercises
Study: NCT03584854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15-methyl prostaglandin F2α
Description: Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15-methyl prostaglandin F2α
Description: Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylergonovine Maleate
Description: Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylergonovine Maleate
Description: Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost.
Study: NCT03477617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative Hemodynamic Algorithm
Description: Anesthesiologists are instructed to use the study's algorithm to manage intraoperative hypotension in response to the cardiac output monitor values.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Usual hemodynamic management
Description: Anesthesiologists are instructed to manage intraoperative hypotension based on their usual clinical care, without information from cardiac output monitor
Study: NCT04121312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitation Intervention
Description: See arm description
Study: NCT03071549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trichloroacetic acid peel
Description: Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined azaleic and salicylic acids
Description: Skin degreasing will be performed before every session using acetone. Azaleic acid 20% with salicylic acid 20% will be applied to the other side of the face.
Study: NCT03573128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Students with Autism Accessing General Education
Description: With study team coach support, teacher implemented modules addressing student behavioral/academic goals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Services As Usual
Description: Teaching staff access in-service presentations and print materials with no active study team coaching.
Study: NCT00916370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core size Xience Prime
Description: Core size includes a range of stent sizes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience Prime Long Lesion (LL)
Description: Long lesion stent sizes include a range of sizes.
Study: NCT01346371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refresh Tears 0.5% Lubricant Eye Drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bepreve 1.5% Ophthalmic Solution
Study: NCT02011126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat Sodium
Description: Given IV
Study: NCT01824745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive the SCP-BCS template booklet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive the SCP-BCS template booklet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Receive counseling sessions with a patient navigator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Description: Receive standard follow-up care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT00765934

Intervention type: DRUG
Group type: OTHER
Intervention: Rapydan
Description: lidocaine / tetracaine 70/70 mg patch
Study: NCT02011126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study: NCT02770495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Study: NCT00687076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin therapy
Description: Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin therapy
Description: Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)